🔴 Gilead Sciences is trading 4.07% down in pre-market as the catalyst remains unclear

Gilead Sciences is trading at $160.75, down 4.07%, in pre-market, with no clear company-specific news explaining the decline.

• Gilead announced positive Phase 3 Livdelzi results on November 5; 75.4% of treated participants achieved the study’s ALP-normalization endpoint, but the update does not explain the drop.
• The recent quarterly report showed higher sales guidance, but is older context.
• Available coverage attributed the prior session’s decline to profit-taking after earnings; the further pre-market move remains unclear.